Company: APM
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001213900-25-037669
Chunk: 9

Company: Aptorum Group Ltd
Filing Date: 2025-04-30
Form: 20-F
Item: Item 3
Chunk 9
---
 be insufficient or inadequate; and                                    
  our drug candidates may cause adverse events, have undesirable side effects or other unexpected characteristics, causing us, our investigators, or regulators to suspend or terminate the trials.     

If we are required to conduct
additional clinical trials or other testing of our drug candidates beyond those that we currently contemplate, if we are unable to successfully
complete clinical trials of our drug candidates or other testing, if the results of these trials or tests are not positive or are only
modestly positive or if they raise safety concerns, we may:

  be delayed in obtaining regulatory approval for our drug candidates;  
  not obtain regulatory approval at all;                                

  obtain approval for indications that are not as broad as intended;        
 ────────────────────────────────────────────────────────────────────────────
  have a drug removed from the market after obtaining regulatory approval;  
  be subject to additional post-marketing testing requirements;             
  be subject to restrictions on how a drug is distributed or used; or       
  be unable to obtain reimbursement for use of a drug.                      

Delays in testing or approvals
may result in increases in our drug development costs. We do not know whether any clinical trials will begin as planned, will need to
be restructured, or will be completed on schedule, or at all. Clinical trials may produce negative or inconclusive results. Moreover,
these trials may be delayed or proceed less quickly than intended. Delays in completing our clinical trials will increase our costs, slow
down our drug candidate development and approval process, and jeopardize our ability to commence product sales and generate revenues and
we may not have sufficient funding to complete the testing and approval process. Any of these events may significantly harm our business,
financial condition and prospects, lead to the denial of regulatory approval of our drug candidates or allow our competitors to bring
drugs to market before we do, impairing our ability to commercialize our drugs if and when approved.

Significant clinical trial
delays also could shorten any periods during which we have the exclusive right to commercialize our drug candidates or allow our competitors
to bring products to market before we do, impair our ability to commercialize our drug candidates and may harm our business and results
of operations.

We may in the future conduct clinical trials
for our drug candidates in sites outside the U. S. and the FDA may not accept data from trials conducted in such locations.

We may in the future conduct
certain of our clinical trials outside the U. S. Although